CARLSBAD, Calif. & ABINGDON, England--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced an extension to its partnership with Chroma Therapeutics Ltd. As a part of this partnership, Invitrogen will use its SelectScreen™ platform to perform biochemical screening on Chroma’s multi-targeted kinase inhibitors at Invitrogen’s Paisley, Scotland, UK, facility. Financial details of the collaboration were not disclosed.
